Mpox vaccine trial for infants: could a Half-Dose protect just as well?
NCT ID NCT06844487
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 study is testing the MVA-BN mpox vaccine in 344 infants and children aged 4 to 24 months in the Democratic Republic of the Congo, a region heavily affected by mpox. Researchers are comparing a standard dose to a half-dose to see if the lower dose is still effective and causes fewer side effects. The goal is to find the best way to protect young children from mpox.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MVA-BN vaccine (Modified Vaccinia Ankara-Bavarian Nordic)
What this could lead to
If successful, this could show that a lower dose of the mpox vaccine is safe and effective for infants and young children, helping protect a high-risk population.
What could go wrong
This is an early-stage trial in a specific region, and results may not apply to other populations. The half-dose might not trigger a strong enough immune response, and side effects in infants are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHILDREN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boende Hôpital Général de Référence, Boende
Boende, La Tshuapa, Democratic Republic of the Congo